Carol Forsblom1, John Moran2, Valma Harjutsalo3, Tony Loughman4, Johan Wadén1, Nina Tolonen1, Lena Thorn1, Markku Saraheimo1, Daniel Gordin1, Per-Henrik Groop5, Merlin C Thomas6. 1. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, FinlandDepartment of Nephrology, Department of Medicine, Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland. 2. Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, South Australia, Australia. 3. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, FinlandDepartment of Nephrology, Department of Medicine, Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, FinlandDiabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland. 4. EKF Diagnostics, London, U.K. 5. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, FinlandDepartment of Nephrology, Department of Medicine, Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, FinlandBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia per-henrik.groop@helsinki.fi. 6. Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, FinlandBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Abstract
OBJECTIVE: Recent studies have suggested that circulating levels of the tumor necrosis factor-α receptor 1 (sTNFαR1) may be a useful predictor for the risk of end-stage renal disease (ESRD) in patients with diabetes. However, its potential utility as a biomarker has not been formally quantified. RESEARCH DESIGN AND METHODS: Circulating levels of sTNFαR1 were assessed in 429 patients with type 1 diabetes and overt nephropathy from the Finnish Diabetic Nephropathy (FinnDiane) cohort study. Predictors of incident ESRD over a median of 9.4 years of follow-up were determined by Cox regression and Fine-Gray competing risk analyses. The added value of sTNFαR1 was estimated via time-dependent receiver operating characteristic curves, net reclassification index (NRI), and integrated discrimination improvement (IDI) for survival data. RESULTS: A total of 130 individuals developed ESRD (28%; ESRD incidence rate of 3.4% per year). In cause-specific modeling, after adjusting for baseline renal status, predictors of increased incidence of ESRD in patients with overt nephropathy were an elevated HbA1c, shorter duration of diabetes, and circulating levels of sTNFαR1. Notably, sTNFαR1 outperformed estimated glomerular filtration rate in terms of R(2). Circulating levels of the sTNFαR1 also remained associated with ESRD after adjusting for the competing risk of death. A prediction model including sTNFαR1 (as a -0.5 fractional polynomial) was superior to a model without it, as demonstrated by better global fit, an increment of R(2), the C index, and area under the curve. Estimates of IDI and NRI(>0) were 0.22 (95% CI 0.16-0.28; P < 0.0001) and 0.98 (0.78-1.23; P < 0.0001), respectively. The median increment in the risk score after including sTNFαR1 in the prediction model was 0.18 (0.12-0.30; P < 0.0001). CONCLUSIONS: Circulating levels of sTNFαR1 are independently associated with the cumulative incidence of ESRD. This association is both significant and biologically plausible and appears to provide added value as a biomarker, based on the absolute values of NRI and IDI.
OBJECTIVE: Recent studies have suggested that circulating levels of the tumor necrosis factor-α receptor 1 (sTNFαR1) may be a useful predictor for the risk of end-stage renal disease (ESRD) in patients with diabetes. However, its potential utility as a biomarker has not been formally quantified. RESEARCH DESIGN AND METHODS: Circulating levels of sTNFαR1 were assessed in 429 patients with type 1 diabetes and overt nephropathy from the Finnish Diabetic Nephropathy (FinnDiane) cohort study. Predictors of incident ESRD over a median of 9.4 years of follow-up were determined by Cox regression and Fine-Gray competing risk analyses. The added value of sTNFαR1 was estimated via time-dependent receiver operating characteristic curves, net reclassification index (NRI), and integrated discrimination improvement (IDI) for survival data. RESULTS: A total of 130 individuals developed ESRD (28%; ESRD incidence rate of 3.4% per year). In cause-specific modeling, after adjusting for baseline renal status, predictors of increased incidence of ESRD in patients with overt nephropathy were an elevated HbA1c, shorter duration of diabetes, and circulating levels of sTNFαR1. Notably, sTNFαR1 outperformed estimated glomerular filtration rate in terms of R(2). Circulating levels of the sTNFαR1 also remained associated with ESRD after adjusting for the competing risk of death. A prediction model including sTNFαR1 (as a -0.5 fractional polynomial) was superior to a model without it, as demonstrated by better global fit, an increment of R(2), the C index, and area under the curve. Estimates of IDI and NRI(>0) were 0.22 (95% CI 0.16-0.28; P < 0.0001) and 0.98 (0.78-1.23; P < 0.0001), respectively. The median increment in the risk score after including sTNFαR1 in the prediction model was 0.18 (0.12-0.30; P < 0.0001). CONCLUSIONS: Circulating levels of sTNFαR1 are independently associated with the cumulative incidence of ESRD. This association is both significant and biologically plausible and appears to provide added value as a biomarker, based on the absolute values of NRI and IDI.
Authors: Katsuhito Ihara; Jan Skupien; Bozena Krolewski; Zaipul I Md Dom; Kristina O'Neil; Eiichiro Satake; Hiroki Kobayashi; Narges M Rashidi; Monika A Niewczas; Andrzej S Krolewski Journal: Kidney Int Date: 2020-07-25 Impact factor: 10.612
Authors: Masayuki Yamanouchi; Jan Skupien; Monika A Niewczas; Adam M Smiles; Alessandro Doria; Robert C Stanton; Andrzej T Galecki; Kevin L Duffin; Nick Pullen; Matthew D Breyer; Joseph V Bonventre; James H Warram; Andrzej S Krolewski Journal: Kidney Int Date: 2017-04-07 Impact factor: 10.612
Authors: Christine P Limonte; Erkka Valo; Daniel Montemayor; Farsad Afshinnia; Tarunveer S Ahluwalia; Tina Costacou; Manjula Darshi; Carol Forsblom; Andrew N Hoofnagle; Per-Henrik Groop; Rachel G Miller; Trevor J Orchard; Subramaniam Pennathur; Peter Rossing; Niina Sandholm; Janet K Snell-Bergeon; Hongping Ye; Jing Zhang; Loki Natarajan; Ian H de Boer; Kumar Sharma Journal: Am J Nephrol Date: 2020-10-14 Impact factor: 3.754
Authors: Brad P Dieter; Sterling M McPherson; Maryam Afkarian; Ian H de Boer; Rajnish Mehrotra; Robert Short; Celestina Barbosa-Leiker; Radica Z Alicic; Rick L Meek; Katherine R Tuttle Journal: J Diabetes Complications Date: 2016-07-27 Impact factor: 2.852
Authors: Meda E Pavkov; E Jennifer Weil; Gudeta D Fufaa; Robert G Nelson; Kevin V Lemley; William C Knowler; Monika A Niewczas; Andrzej S Krolewski Journal: Kidney Int Date: 2016-01-04 Impact factor: 10.612